Survodutide Timeline Boehringer Ingelheims SYNCHRONIZE program includes multiple Phase 3 trials: SYNCHRONIZE-1: Obesity without type 2 diabetes (726 participants, 76 weeks) SYNCHRONIZE-2: Obesity with type 2 diabetes (755 participants, 76 weeks) SYNCHRONIZE-CVOT: Cardiovascular outcomes (4,935 participants target) LIVERAGE trials: MASH-specific studies initiated October 2024 FDA Breakthrough Therapy designation for MASH may accelerate review for that indication specifically
Increased excretions of 2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis
Un aumento de la energa en cualquier deporte especialmente en aquellos que tienen una duracin de ms de 30 minutos
It has also been found to have potential benefits for certain conditions such as male infertility and insulin resistance
Pricing is shown per unit across 50, 100+, and 250+ unit tiers
They introduced the recognition motif LPETG to the C-termini of the light and heavy chains of various mAbs
